Portola Pharmaceuticals Inc. buy klostergang
Summary
This prediction ended on 19.04.20 with a price of €5.77. The BUY prediction by klostergang for Portola Pharmaceuticals Inc. performed very badly with a performance of -88.43%. klostergang has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Portola Pharmaceuticals Inc. | 0.012% | 0.012% | -32.057% | -67.867% |
iShares Core DAX® | 1.080% | -2.131% | 14.264% | 15.290% |
iShares Nasdaq 100 | 0.362% | 7.059% | 35.383% | 56.103% |
iShares Nikkei 225® | -1.155% | -0.483% | 8.258% | 4.324% |
iShares S&P 500 | 0.806% | 5.037% | 29.635% | 49.529% |
Comments by klostergang for this prediction
In the thread Portola Pharmaceuticals Inc. diskutieren
PORTOLA a potential takeover candidate
klostergang stimmt am 27.06.2017 der Outperform-Einschätzung der institutionellen Analysten mit dem Kursziel 70$ zu.
The shares surged again last week as the FDA granted approval to its compound BEVYXXA (betrixaban) which is an extended-duration anticoagulant, for the prevention of venous thromboembolism {VTE} in
hospitalized at-risk adult patients. Another huge potential catalyst is coming up in mid-August, this is when the FDA should approve Portfola’s second drug candidate ‘Andexx'.
I could see Portola becoming a logical buyout target by a larger player with an established sales force. This may be one reason that Oppenheimer, Morgan Stanly, Cowen & Co. and Citigroup all reissued Buy ratings yesterday with price targets proffered between $66 and $78 a share.
Cowen raised their price target from $45 to $70 and Citigroup went from $51 to $78 while mentioning Portola as a potential takeover candidate.
In the thread Trading Portola Pharmaceuticals Inc.
Stopped prediction by klostergang for Portola Pharmaceuticals Inc.
Portola Pharmaceuticals Inc.
03.06.15
07.12.15
07.12.15